Ir para o conteúdo principal

TG Therapeutics (NASDAQ: TGTX) — Perfil da empresa, notícias e dados financeiros

Logo de TG Therapeutics
TGTX TG Therapeutics
TG Therapeutics primary media
Perfil da empresa

TG Therapeutics

TG Therapeutics (NASDAQ:TGTX) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies and autoimmune diseases. Their pipeline consists of innovative, novel treatments aimed at improving the quality of life for patients with B-cell malignancies and autoimmune diseases. With a commitment to addressing unmet medical needs, TG Therapeutics is dedicated to advancing its research and development projects to bring next-generation therapies to the market. Targeting specific diseases with precision medicine, their objective is to provide more effective and less toxic treatment options, spearheading a new era in patient care.

Resumo

Public USParticipação acionária
1993Ano de fundação
325Funcionários
North Carolina, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de TG Therapeutics

  • UKONIQ (umbralisib), an innovative treatment for marginal zone lymphoma and follicular lymphoma.
  • BET Inhibitors, a novel class targeting hematologic malignancies and autoimmune diseases.
  • Anti-CD47 Monoclonal Antibody, aimed at enhancing the immune system's ability to fight cancer.
  • MS Therapeutics, focusing on novel treatments for multiple sclerosis.
  • PI3K Delta Inhibitor Program, targeting a range of hematologic cancers.
  • BTK Inhibitor Program, aimed at developing next-generation therapies for B-cell malignancies.

equipe executiva do TG Therapeutics

  • Michael S. WeissChairman, CEO & President
  • Sean A. PowerCFO, Corporate Secretary & Treasurer
  • Jenna BoscoSenior Vice President of Corporate Communications
  • Adam WaldmanChief Commercialization Officer

Principais indicadores financeiros

Resultados divulgados pela TG Therapeutics, em USD.

Cap. de mercado
8,6 bi
Receita (TTM)
799,5 mi
P/L
20.5
LPA (diluído, TTM)
2.8
Dividend yield
—
Margem de lucro
55.2%
Receita e lucro anuais da TG Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
616,3 mi123,3 mi447,2 mi
329 mi41,9 mi23,4 mi
233,7 mi20,6 mi12,7 mi
2,8 mi-218,3 mi-223,8 mi